Fast track — Research LettersSevere acute interstitial pneumonia and gefitinib
Summary
Gefitinib is an oral selective inhibitor of the epidermal growth factor receptor tyrosine kinase that is an effective treatment for patients with advanced non-small cell lung cancer who do not respond to platinum-based chemotherapy. We assessed four patients who had non-small cell lung cancer causing severe acute interstitial pneumonia in association with gefitinib. Although two patients recovered after treatment with steroids, the other two died from progressive respiratory dysfunction. On the basis of autopsies and bilateral distribution of diffuse ground-glass opacities in chest CTs, we diagnosed diffuse alveolar damage, which was consistent with acute interstitial pneumonia. Patients with interstitial pneumonia also had other pulmonary disorders such as previous thoracic irradiation and poor performance status. Physicians should be aware of the alveolar damage induced by gefitinib, especially for patients with these characteristic features.
References (5)
- FukuokaM et al.
Final results from a phase II trial of ZD1839 (‘Iressa’) for patients with advanced non-small cell lung cancer (IDEAL 1)
Proc Am Soc Clin Oncol
(2002) - KrisMG et al.
A phase II trial of ZD1839 (‘Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2)
Proc Am Soc Clin Oncol
(2002)
Cited by (470)
Réanimation en oncologie thoracique
2023, Revue des Maladies Respiratoires ActualitesDepuis plusieurs années, les thérapies ciblées et l’immunothérapie ont considérablement amélioré le pronostic des patients avec un cancer bronchique non à petites cellules. De nouvelles questions se posent donc concernant l’admission de ces patients en réanimation. Cette question peut se poser au diagnostic, avant l’initiation de ces nouveaux traitements, ou en cours de traitement, notamment pour gérer certains effets secondaires graves. Une collaboration étroite entre oncologues et médecins intensivistes et réanimateurs est indispensable pour une prise en charge optimale de ces patients.
Dans cette revue, nous décrivons les facteurs associés à la survie en réanimation des patients avec un cancer bronchique : qu’ils soient liés au patient, à la tumeur ou à la situation aiguë. Les circonstances dans lesquelles la question d’admission en réanimation se pose sont également discutées.
1877-1203/© 2023 SPLF. Publié par Elsevier Masson SAS. Tous droits réservés.
Over several years, immunotherapy and targeted therapy have considerably improved the prognosis of patients with non-small cell lung cancer. New questions arise regarding their potential intensive care unit admission.
This question may arise at diagnosis, before the initiation of these new treatments, or during treatment, particularly to manage serious side effects. Close collaboration between oncologists and intensivists is essential for optimal management of these patients.
In this review, we describe the factors associated with ICU survival in patients with lung cancer: whether they are related to the patient, the tumor or the acute situation. The circumstances in which the question of admission to the ICU arises are also discussed.
1877-1203/© 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
2023, Revue des Maladies Respiratoires ActualitesLa concomitance d’un cancer bronchique et d’une pneumopathie interstitielle diffuse (PID) fibrosante n’est ni fortuite ni exceptionnelle. Les modalités diagnostiques et thérapeutiques sont cependant actuellement mal standardisées, et il n’existe pas de consensus d’experts disponible en Europe. Les stratégies thérapeutiques se heurtent aux limitations liées à la fonction respiratoire sous-jacente, au risque d’exacerbation respiratoire favorisée par certains traitements, ainsi qu’à l’âge, aux comorbidités et, de façon générale, à la fragilité sous-jacente des patients avec fibrose pulmonaire. Dans cet article, nous ferons le point sur l’épidémiologie, la prise en charge diagnostique et les éléments nécessaires pour discuter des stratégies thérapeutiques locorégionales et systémiques.
1877-1203/© 2023 SPLF. Publié par Elsevier Masson SAS. Tous droits réservés.
The occurrence of lung cancer in patients with diffuse fibrosing pneumonitis is neither fortuitous nor rare. Diagnosis strategy and therapeutics are currently poorly standardized, and there is no expert consensus available in Europe. Therapeutic strategy is limited by the poor underlying respiratory function, the risk of respiratory exacerbation favored by some treatments, age and comorbidities, and more generally by the underlying frailty of patients with lung fibrosis. In the current article we will review the epidemiology, the diagnosis management, and the necessary data for discussing locoregional or systemic therapeutic strategies.
1877-1203/© 2023 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Valsartan prevents gefitinib-induced lung inflammation, oxidative stress, and alteration of plasma metabolites in rats
2023, Saudi Journal of Biological SciencesGefitinib (GEF) is an inhibitor of the epidermal growth factor receptor, linked to higher risk of severe/fatal interstitial lung disease (ILD). This study was performed to determine the protective roles of an angiotensin-II type-1 receptor (AT1R) “valsartan (VAL)” in prevention of lung inflammation, oxidative stress and metabolites alteration induced by GEF. Four groups of male Wistar albino rats were received vehicle, VAL (30 mg/kg), GEF (30 mg/kg), or both for four weeks. Blood samples and lungs were harvested for plasma metabolites and histological analysis, respectively, and evaluation of inflammation and oxidative stress. GEF monotherapy showed a dense inflammation in lungs, and significantly increased tumor necrosis factor-α (P = 0.0349), interleukin-6 (P < 0.0001), chemokine ligand-3 (P = 0.0420), and interleukin-1β (P = 0.0377). GEF increased oxidative stress markers including glutathione, malondialdehyde, and catalase levels. Also, several plasma metabolites including butanoic acid, N-methylphenylethanolamine, oxalic acid, l-alanine, phosphoric acid, l-theorinine, pyroglutamic acid, and 2-bromosebacic acid were changed by GEF. The combination of VAL plus GEF reduced the inflammation and oxidative stress mediated by GEF monotherapy. In addition, the combination treatment returned plasma metabolites to the normal levels compared to GEF monotherapy. These findings revealed that VAL has a possible pulmonary protective role against pulmonary toxicity of GEF, which may lead to novel approaches for management of GEF-induced ILD.
Osimertinib has demonstrated impressive efficacy as a first-line treatment for patients with advanced epidermal growth factor receptor (EGFR) mutation-positive (m+) lung cancer. Drug-related pneumonitis (DRP) is a potentially lethal complication of osimertinib treatment, but reliable real-world data currently are lacking.
What is the prevalence of osimertinib-induced DRP in first-line settings? What are the characteristics, clinical impact, and risk factors of osimertinib-induced DRP?
We conducted a retrospective multicenter cohort study of patients who received osimertinib as a first-line treatment for advanced EGFR m+ non-small cell lung cancer (NSCLC) between August 2018 and December 2019. All chest CT scans and clinical information during osimertinib exposure were collected until June 2020. The primary end point was DRP incidence identified through central review.
A total of 452 patients from 18 institutions were evaluated. Eighty patients (18%) had a diagnosis of DRP (all grades), and 21 patients (4.6%) had a diagnosis of grade 3 or more DRP. Among the patients with DRP, 46% were identified as having transient asymptomatic pulmonary opacity (TAPO). Regarding the CT scan patterns, organizing pneumonia, simple pulmonary eosinophilia, hypersensitivity pneumonia, diffuse alveolar damage, and nonspecific interstitial pneumonia were found in 30, 21, 18, 9, and two patients (38%, 26%, 23%, 11%, and 3%), respectively. In multivariate analysis, smoking history was identified as an independent risk factor for DRP (hazard ratio, 1.72; 95% CI, 1.01-2.89; P = .046). In the 3-month landmark analysis, DRP was associated with poor treatment efficacy; however, the presence of TAPO did not affect treatment efficacy negatively.
For osimertinib treatment in first-line settings, the frequency of DRP was considerably elevated to 18 %, and half of these patients exhibited TAPO features.
Cancers pulmonaires associés à une pathologie interstitielle pulmonaire fibrosante
2022, Revue des Maladies Respiratoires ActualitesLa concomitance d’un cancer bronchique et d’une pneumopathie interstitielle diffuses (PID) fibrosante n’est ni fortuite ni exceptionnelle. Les modalités diagnostiques et thérapeutiques sont cependant actuellement mal standardisées, et il n’existe pas de consensus d’experts disponible en Europe. Les stratégies thérapeutiques se heurtent aux limitations liées à la fonction respiratoire sous-jacente, au risque d’exacerbation respiratoire favorisée par certains traitements, ainsi qu’’à l’âge, aux comorbidités et de façon générale, à la fragilité sous-jacente des patients avec fibrose pulmonaire. Dans cet article nous ferons le point sur l’épidémiologie, la prise en charge diagnostique et les éléments nécessaires pour discuter des stratégies locales et systémiques.
1877-1203/© 2022 SPLF. Publié par Elsevier Masson SAS. Tous droits réservés.
The occurrence of lung cancer in patients with diffuse fibrosing pneumonitis is neither fortuitous nor rare. Diagnosis strategy and therapeutics are currently poorly standardized, and there is no expert consensus available in Europe. Therapeutic strategy is limited by the poor underlying respiratory function, the risk of respiratory exacerbation favored by some treatments, age and comorbidities, and more generally by the underlying frailty of patients with lung fibrosis. In the current article we will review the epidemiology, the diagnosis management, and the necessary data for discussing local or systemic therapeutics.
1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Chronic diffuse lung diseases
2022, Practical Pulmonary Pathology: A Diagnostic ApproachChronic diffuse lung diseases are dominated by a spectrum of nonneoplastic, mainly inflammatory, conditions that affect the lung parenchyma. Prominent in these conditions are the idiopathic interstitial pneumonias, pulmonary manifestations of systemic collagen vascular disease, diffuse eosinophilic lung disease, drug-associated lung disease, diffuse granulomatous lung disease, and a variety of miscellaneous diseases that remain enigmatic in terms of etiology and/or pathogenesis. Individual entities are reviewed, followed by a section highlighting a practical approach to the four most common patterns of injury encountered in practice.